AF
GBT

Amalgamated Financial’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Amalgamated Financial’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$350K Buy
+10,100
New +$302K ﹤0.01% 1669

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Amalgamated Financial's GBT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Global Blood Therapeutics, Inc. (GBT) in Q1 2022: 10,100 shares worth $350K. The stake represents ﹤0.01% of the portfolio and ranks #1669 among its holdings.

204 funds tracked by Wall St. Rank hold GBT as of Q1 2022.

  • Amalgamated Financial held 10,100 shares of Global Blood Therapeutics, Inc. worth $350K as of Q1 2022.
  • Global Blood Therapeutics, Inc. was a new Amalgamated Financial position in Q1 2022.
  • Global Blood Therapeutics, Inc. made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1669 holding.
  • 204 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.